Twiz, I posted the answer to this last night on the ONCS and INO thread. Its mostly about combination adjuvant approaches including the PD1 and IL-12 vaccine combination. It may be more effective than either adjuvant alone. But I think because of the nature of melanoma (it hides from the immune system quite well), adjuvant approaches alone may not be enough. David Baltimore's group (nobel prize winner back in the 70s who has been important for so many discoveries in innate and adaptive immunity), and other prominent groups of scientists, are currently looking at (and have major NIH sponsored program project grants) specific individualized melanoma vaccines for patients based on the aberrant proteins that are expressed by their particular melanoma cells. They are looking at the antigens. ONCS, BMY, MRK, Roche, are looking at adjuvants. I think when these approaches are combined, the best results will be obtained.
As far as the ONCS collaboration with ODU, Dr. Heller's specialty is in electrophysiology, not really in immunity. I know he is currently looking at IL-15 as a potential adjuvant. He just may be in charge of the trial, but ODU is a research institute and not a hospital. I know he has connections to USF, where Moffitt Cancer Center, one of the premier cancer institutes in the country that run melanoma trials. If he piggybacks with oncologists at Moffitt, to get melanoma patients, then I can see this being a potentially very useful collaboration.